Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes and obesity, and reduce cardiovascular risk. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is a daily pill. Rybelsus TM was approved by the U.S. FDA in September 2019 as the first GLP-1 analog that does not need to be injected.

NLRP3 inhibitor must pass into brain to effect weight loss in obese mice. The inhibitor calms microgliosis in the hypothalamus, raising hopes for such effects in other brain areas. TN-783 complemented semaglutide, promoting further weight loss after the GLP-1 mimetic had plateaued.

Microglia Open a Metabolic Pipeline for Active Neurons You probably knew that astrocytes provide neurons with lactate during periods of intense activity to fuel these cells' extreme energy demand. Yes, that would be the astrocyte-neuron lactate shuttle. But did you know which cells orchestrate this pipeline? Microglia, via endothelial cells. Read about it, and the role of CYR61 and GLUT1, in ...

Semaglutide mildly shifted some CSF AD biomarkers, although the drug is not expected to reduce amyloid. Some scientists believe semaglutide could prevent AD or other dementias, if started earlier.

AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.

Background NT-0796 is an oral, brain-penetrant inhibitor of inflammasomes that contain NLRP3, aka nod-like receptor family pyrin domain-containing protein 3. Inflammasomes are multiprotein, cytosolic complexes that function as sensors in the innate immune system. They are found in microglia in the brain, and in monocytes and macrophages outside the brain. Their activation by pathologic ...

Background Liraglutide is an analog of glucagon-like peptide 1. GLP-1 is a hormone that is produced in the gut and activates receptors in the gut, liver, and pancreas to control blood-sugar levels and reduce insulin resistance. Liraglutide and related GLP-1 mimetics cause body weight loss and reduce the risk of cardiovascular events, stroke, and dementia in people with diabetes.

Semaglutide Does Not Treat Alzheimer’s. Could It Prevent Dementia? Add To My AlzForum 1 comments 16 Dec 2025

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716.

Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331 (18):1519-1521. PubMed.